Bought allot of shares at the last offer and will be adding as we go up.My guess this stock will be 50% higher from the offer in the near term. 1.20s tomm and maybe 1.50s early jan 14
Your post makes no sense.FDA says whats naturally produced when a womens pregnat is un-safe to funny.
Synthetic Biologics, Inc. April 4, 2013 1:30 PM
ROCKVILLE, Md., April 4, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,372,826 entitled, Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases, to the Regents of the University of California which includes claims to the use of the Company's drug candidate, Trimesta™ (oral estriol), in combination with glatiramer acetate injection (Copaxone®). Copaxone® is the number one selling drug for multiple sclerosis with approximately $4 billion in annual sales. Currently marketed exclusively by Teva Pharmaceutical Industries Ltd., Copaxone® is expected to face generic competition as certain patent terms begin to expire in 2014. Through its wholly owned subsidiary, Synthetic Biologics holds the exclusive worldwide license to U.S. Patent 8,372,826 and 6,936,599 and pending patents for multiple sclerosis and other autoimmune diseases covering the uses of its drug candidate, Trimesta™.
Trimesta™ is currently being utilized in combination with Copaxone® in a randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of relapsing-remitting multiple sclerosis in women. Lead Principal investigator, Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, along with investigators at 14 other centers in the U.S., are administering either Trimesta™ (8 milligrams orally per day) in combination with Copaxone® (20 milligrams per day), or a placebo plus Copaxone® to patients enrolled in the trial.
"The claims in this new patent further expand Synthetic Biologics' coverage of our proprietary oral estriol product candidate, Trimesta™, to include its use in combination with the leading FDA-approved multiple sclerosis drug, Copaxone®," stated Jeffrey Riley, Chief Executive Officer at Synthetic Biologics. "We look forward to reporting the clinical results of this combination therapy after the relapsing-remitting multiple sclerosis patients complete their two years of dosing and monitoring scheduled for January 2014."
Our team has been on this for two days now. Traded it twice today myself and bought it big 5 minutes before the close at .0109 and sold then all at .0151 at the closing auction 16:00:20. That was almost a 50% gain in less then 3 minutes time tigers! OLIE was a pick from one of our mods and its up over 500% from his alert.
So you guys see i alerted that stock at 3.00 today and we unloaded the pop.Sorry been doing it for the last couple days.CREG was my alert yesterday at 4.00 we got 4.60s PM today and IDRA was my swing today. OLIE was our groups sub play the last days. Just thought you guys might like to know why nuro pops and drops allot.I'm bullish though on nuro
A powerful rally is setting up for shares in SYN.My guess this could see a quick 50% bounce and more then 100% run into the MS data. Randal Kirk isn't dumb money
Watch the last swing break of 2.02 then 2.10. After that I'm looking for the 2.50s. Keep ROX on your list .Looking for a break of the 52 week high at 1.10s. After the BEAM take over for 14 billion Rox will be seeing action.